Avista Healthcare

Yardley, PA, January 28, 2016 – OptiNose, a privately-held specialty biopharmaceutical company, today announced that its licensing partner, Avanir Pharmaceuticals, Inc. has reported that the U.S. Food & Drug Administration (FDA) approved ONZETRA™ Xsail™ (sumatriptan nasal powder), formerly AVP-825, for the acute treatment of migraine with or without aura in adults (see Full Prescribing Information […]

SAYREVILLE, N.J. and MARIETTA, GA., December 4, 2015 – Vertical / Trigen Holdings, LLC (“Vertical / Trigen”) and Osmotica Holdings Corp Limited (“Osmotica”) today announced that they have entered into a definitive agreement to combine, creating a world-class, fully-integrated specialty pharmaceutical and generics company. Vertical / Trigen is a portfolio company of Avista Capital Partners […]

Raleigh, N.C., Dec. 3, 2015 – INC Research Holdings, Inc. (INC Research)(Nasdaq: INCR), a leading, global Phase I to IV contract research organization, today announced the Company was named “Best Contract Research Organization” at the 11th Annual Scrip Awards held Dec. 2 in London. INC was selected from among several leading global CROs by a […]

Raleigh, N.C., December 2, 2015 – INC Research Holdings, Inc. (Nasdaq: INCR) (the “Company”), a leading global Phase I to Phase IV contract research organization, today announced the pricing of an underwritten secondary offering by certain of its existing stockholders, namely affiliates of Avista Capital Partners, L.P. and affiliates of Ontario Teachers’ Pension Plan, of […]

Effective October 1, 2015, Acino Pharma, an international pharmaceutical company headquartered in Switzerland, acquires Pharma Start, the 9th largest local pharmaceutical company in Ukraine. The acquisition is in line with Acino’s strategy to grow its business by entering selected high potential emerging markets in the CIS Region (Commonwealth of Independent States) in addition to selected […]

Yardley, PA, September 24, 2015 – OptiNose today announced positive results from a second phase III pivotal trial, NAVIGATE I. This follows and helps both to confirm and support the positive results from a first pivotal trial, NAVIGATE II, that were announced in June. The NAVIGATE trials are double-blind, placebo-controlled studies evaluating the safety and […]

Trimb Healthcare AB (“Trimb”) today announced that it has signed an agreement to acquire YouMedical Group BV (“YouMedical”), a Dutch OTC company with operations in key European markets. YouMedical has total annual sales of approximately EUR 16 million, with solid growth and leading brands in niche categories. “Our ambition is to build a leading international […]

Raleigh, N.C., August 11, 2015 (GLOBE NEWSWIRE) — INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to Phase IV contract research organization, announced the pricing of its secondary offering of 8,000,000 shares of its Class A common stock by certain of its existing stockholders, including affiliates of Avista Capital Partners, L.P.; affiliates of […]

Trimb Healthcare AB (“Trimb”) and Avista Capital Partners (“Avista”), a leading private equity firm, today announced that Avista is partnering with the company’s founders and management, as well as its founding investor, HealthCap, to build Trimb into a leading OTC and consumer healthcare company. Avista has made a significant capital commitment to accelerate Trimb’s growth […]

N. Billerica, MA – June 24, 2015 – Lantheus Holdings, Inc. (“Lantheus Holdings” or the “Company”), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products, announced today the pricing of its initial public offering of 10,833,334 shares of its common […]

Yardley, PA, June 24, 2015 – (Business Wire) OptiNose today announced positive results from its first phase III controlled clinical trial, NAVIGATE II, evaluating the safety and efficacy of OPN-375, an investigational treatment for nasal polyps, a type of Chronic Nasal Inflammatory Disease (CNID), and the associated chronic symptoms. OPN-375 demonstrated statistically significant effects on […]

Raleigh, N.C., May 7, 2015 – INC Research Holdings, Inc. (Nasdaq: INCR), a leading global Phase I to Phase IV contract research organization, announced the pricing of its secondary offering of 7,000,000 shares of its Class A common stock at a price of $31.00 per share. All of the shares are being sold by existing […]